Jubilant Pharmova USFDA Inspection with 8 Observations

Date: June 19, 2026

Regulatory Compliance Update

USFDA Inspection Outcome

• The United States Food and Drug Administration (USFDA) completed an inspection of Jubilant HollisterStier LLC's contract manufacturing facility in Spokane, WA, U.S.A.
• The inspection concluded on June 17, 2026.
• The USFDA issued eight (8) observations during the inspection.
• None of the observations are related to sterility assurance concerns.
• Jubilant HollisterStier LLC will respond to the inspection observations within 15 business days.

Corporate Structure Clarification

• Jubilant HollisterStier LLC is a subsidiary of Jubilant Pharma Holding Inc.
• Jubilant Pharma Holding Inc. is a subsidiary of Jubilant Pharma Limited, Singapore.
• Jubilant Pharma Limited, Singapore is a wholly owned subsidiary of Jubilant Pharmova Limited.

Facility Details

• The inspected facility is located in Spokane, WA, U.S.A.
• The facility specializes in contract manufacturing of sterile injectables (both liquid and lyophilization) and ophthalmics (ointment, liquid and creams).

Communication Details

• The company received the inspection outcome on June 17, 2026, at 15:30 PM (PST), which corresponds to June 18, 2026, at 04:00 AM (IST).
• The disclosure was made in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Company Representation

• The announcement was signed by Naresh Kapoor, Company Secretary of Jubilant Pharmova Limited.

No material disclosures under the following sections: KMP / Board / Auditor Changes, Dividend Declaration, Board Meeting Outcomes, Financial Results, Auditor's Report, Disinvestment / Strategic Actions, Media Release / Investor Communication.